Such patients might be deemed false-negatives when using FDA-approved assays (BRCAnalysisTM and FoundationFocusTM), currently used in breast cancer diagnosis and based on the presence of BRCA1/2 mutations, to predict response to poly(ADP-ribose) polymerase (PARP) inhibitors and/or platinum compounds. This evidence concerns the gene BRCA1 and breast cancer.